The Fifth Circuit Court of Appeals just blocked nationwide access to mifepristone by mail and telehealth, effectively reinstating a requirement that the abortion pill be dispensed in person at a clinic or pharmacy. The order, handed down Friday afternoon out of New Orleans, takes effect immediately and is already on a fast track to the Supreme Court.
The ruling came from a three judge panel that sided unanimously with Louisiana, the state that sued the FDA last October to undo a 2023 Biden era rule allowing mifepristone to be prescribed through telehealth and shipped through the mail. Trump appointed Circuit Judge Kyle Duncan wrote the opinion, joined by Judges Leslie Southwick and Kurt Engelhardt. Louisiana Attorney General Liz Murrill wasted no time spiking the football, claiming in a statement that the “Biden abortion cartel” had facilitated the deaths of thousands of Louisiana babies through illegal mail order abortion pills, and saying the nightmare was over.
Mifepristone is one of two drugs used in medication abortion, and the stakes here are enormous. Friday’s ruling is the biggest victory the anti abortion movement has scored against medication abortion since Roe fell, and it lands at a moment when medication abortion accounts for roughly two thirds of all abortions in the United States. After Dobbs, telehealth became the workaround. Providers in states with shield laws were prescribing the pill remotely and mailing it into states where abortion is banned. According to the latest data from the research project #WeCount, more than one in four abortions nationwide were happening through telehealth in the first half of 2025, up from less than one in ten in 2022. That pipeline is now closed, at least temporarily.
Louisiana built its case on a financial argument that turned out to be the whole game. The state pointed to $92,000 paid by Medicaid in 2025 to treat two women who needed emergency care from complications it claimed were caused by out of state mifepristone. The court accepted that as enough harm to give Louisiana legal standing, even though decades of FDA safety reviews and peer reviewed studies show severe complications from mifepristone occur in less than 1% of cases. Judge Duncan wrote that the FDA’s loosening of the rules likely lacked a basis in data and scientific literature, a finding GenBioPro, the company that manufactures generic mifepristone, called alarming and out of step with science.
The cultural read on this is the part most outlets won’t say out loud. Black women die at nearly three times the rate of white women from pregnancy related causes in this country, and the Deep South, where Louisiana sits, is the epicenter. Telehealth abortion was one of the few ways women in restrictive states could quietly access reproductive care without driving across multiple state lines or paying for travel and lodging they cannot afford. Stripping that access back doesn’t make abortion go away. It makes it more expensive, more dangerous, and more concentrated among women with the resources to navigate it.
The Trump administration’s role here is messy. The administration had stopped short of defending the FDA’s regulatory approach on the merits, instead arguing only that Louisiana’s lawsuit had procedural defects. The Fifth Circuit rejected those procedural arguments and went straight to the substance, which is why this ruling lands harder than the typical injunction. Trump’s FDA was supposed to be conducting its own safety review of mifepristone, and reports indicate that review has now been pushed until after the November midterms.
Reproductive rights groups responded immediately. Brittany Fonteno, CEO of the National Abortion Federation, said the ruling is not grounded in science or patient safety and called it a politically driven decision that overrides decades of medical expertise. Nancy Northup of the Center for Reproductive Rights said telehealth has been the last bridge to care for many seeking abortion and that Louisiana officials targeted it precisely because it was working. ACLU senior staff attorney Julia Kaye said anti abortion politicians have just made it much harder for people everywhere in the country to get a medication that abortion and miscarriage patients have been safely using for more than 25 years.
The case is now headed to the Supreme Court, which already declined once to overturn FDA approval of mifepristone in 2024 on standing grounds. This time the standing question is different because Louisiana, a state with both Medicaid costs and an abortion ban on the books, is the plaintiff rather than a group of doctors. That changes the legal calculus, and abortion rights advocates know it.
For now, women in all 50 states, including those where abortion is fully legal, will have to obtain mifepristone in person at a clinic, hospital, or certified pharmacy. The shield laws that allowed providers in states like New York and California to mail pills into Louisiana, Texas, and Mississippi don’t override a federal injunction. The mailbox is closed.
